

South & Central America Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

<https://marketpublishers.com/r/S984827E309AEN.html>

Date: March 2024

Pages: 87

Price: US\$ 3,550.00 (Single User License)

ID: S984827E309AEN

Abstracts

The South & Central America antibody drug conjugates market was valued at US\$ 264.91 million in 2022 and is expected to reach US\$ 799.23 million by 2030; it is estimated to grow at a CAGR of 14.8% from 2022 to 2030.

Escalating Pipeline of ADCs Fuels the South & Central America Antibody Drug Conjugates Market

Various biopharmaceutical companies are developing ADCs owing to the rising interest in ADCs as promising cancer treatment. Companies such as ImmunoGen, Inc; NBE-Therapeutics, Seagen Inc; ADC Therapeutics; Merck KGaA; Sorrento Therapeutics, Inc; Mythic Therapeutics; Sutro Biopharma; Peak Bio; Regeneron Pharmaceuticals; Asana BioSciences; Sanofi; Navrogen, Inc; and OBI Pharma have ADCs in the different developmental phases. It is anticipated that the commercial launch of the ADCs developed will significantly enhance market size.

The companies have developed a broad list of promising ADCs in the different clinical stages and pipelines to be commercialized. The list of ADCs in the pipeline includes Camidanlumab tesirine, ADCT-602, Zynlonta, ADCT-901, ADCT-701, ADCT-212, ADCT-601, Ladiratuzumab Vedotin, NBE-002, IMGN151, IMGN-632, IMGC 936, IMGN-151, OBI 999, R 992, NAV-001, MYTX-011, M1231, STI-6129, Torpedo, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC.

Companies have also shared pre-clinical data related to their respective products. For

instance, in April 2023, Mythic Therapeutics announced preclinical data for its MYTX-011 (cMET-targeting ADC). The data published included the highlights of MYTX-011 intended to treat a broad range of cMET+ cancers. Likewise, at the Association for Cancer Research Annual Meeting in April 2023, Araris Biotech AG announced its preclinical data on anti-Nectin-4 and anti-HER2 ADCs. The two ADCs were developed using the company's proprietary linker technology. The data demonstrated improved anti-tumor activity of anti-Nectin-4 and anti-HER2 ADCs compared to respective FDA-approved ADCs in head-to-head in-vivo studies. Thus, the rise in innovative ADCs will likely propel the market growth exponentially in the coming years.

South & Central America Antibody Drug Conjugates Market Overview

The antibody drug conjugates market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market growth in this region is primarily attributed increasing awareness regarding cancer screening. For instance, the Brazilian Association of Intestinal Cancer Prevention (ABRAPRECI) and the Colorectal Cancer Prevention and Screening Program have been initiated to create awareness among the masses. The growth in awareness campaigns and screening programs has increased the demand for colonoscopy services. In addition, in December 2020, a French diagnostic firm, HaliuDx signed an agreement with Diagnosticos da America (DASA) to distribute its Immunoscore colon cancer risk-assessment test in Brazil. Immunoscore assists in predicting the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites, which helps plan treatment strategies. Under the agreement terms, in Brazil, Sao Paulo-based DASA has exclusive distribution rights to the test, offering it through 40 laboratory networks. As ADCs target specific cancer cells and release toxic drug into the cancer cells, the rising cases of cancer in the country are expected to boost the market in the future. Also, the current plans for colorectal cancer screening in Argentina, the incidence of colorectal cancer is expected to increase shortly due to the discovery of previously undiagnosed diseases. Therefore, these factors are likely to contribute to the progress of the antibody drug conjugates market in Argentina during the forecast period.

South & Central America Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US\$ Million)

South & Central America Antibody Drug Conjugates Market Segmentation

The South & Central America antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the South & Central America antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the South & Central America antibody drug conjugates market

antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the South & Central America antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the South & Central America antibody drug conjugates market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil dominated the South & Central America antibody drug conjugates market in 2022. Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the South & Central America antibody drug conjugates market.

Contents

1. INTRODUCTION

- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Market Attractiveness

3. RESEARCH METHODOLOGY

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

4. SOUTH & CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - KEY INDUSTRY DYNAMICS

- 4.1 Key Market Drivers:
 - 4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
 - 4.1.2 Rising Incidences of Cancer Cases
 - 4.1.3 Increasing FDA Approvals for ADCs
- 4.2 Market Restraints
 - 4.2.1 High Cost of ADCs Development and Commercialization
- 4.3 Market Opportunities
 - 4.3.1 Increasing Investments to Develop ADCs
- 4.4 Market Trends
 - 4.4.1 Escalating Pipeline of ADCs
- 4.5 Impact Analysis:

5. ANTIBODY DRUG CONJUGATES MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS

- 5.1 South & Central America Antibody Drug Conjugates Market Revenue (US\$ Mn), 2017 - 2030

6. SOUTH & CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET -

South & Central America Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology (...)

REVENUE AND FORECAST TO 2030 - BY TECHNOLOGY

6.1 Overview

6.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)

6.3 Cleavable Linker

6.3.1 Overview

6.3.2 Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

6.4 Non-cleavable Linker

6.4.1 Overview

6.4.2 Non-cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

7. SOUTH & CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - REVENUE AND FORECAST TO 2030 - BY APPLICATION

7.1 Overview

7.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)

7.3 Blood Cancer

7.3.1 Overview

7.3.2 Blood Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

7.4 Breast Cancer

7.4.1 Overview

7.4.2 Breast Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

7.5 Ovarian Cancer

7.5.1 Overview

7.5.2 Ovarian Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

7.6 Urothelial Cancer

7.6.1 Overview

7.6.2 Urothelial Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

7.7 Others

7.7.1 Overview

7.7.2 Others: South & Central America Antibody Drug Conjugates Market - Revenue

and Forecast to 2030 (US\$ Million)

8. SOUTH & CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - REVENUE AND FORECAST TO 2030 - BY DISTRIBUTION CHANNEL

8.1 Overview

8.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

8.3 Hospital Pharmacies

8.3.1 Overview

8.3.2 Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

8.4 Retail Pharmacies

8.4.1 Overview

8.4.2 Retail Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

8.5 Online Pharmacies

8.5.1 Overview

8.5.2 Online Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US\$ Million)

9. SOUTH & CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - COUNTRY ANALYSIS

9.1 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030

9.1.1 Overview

9.1.2 South & Central America Antibody Drug Conjugates Market Breakdown, by Country- Revenue (2022) (US\$ Million)

9.1.3 South & Central America: Antibody Drug Conjugates Market, by Countries, 2022 and 2030 (%)

9.1.3.1 Brazil

9.1.3.1.1 Overview

9.1.3.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US\$ Mn)

9.1.3.1.3 Brazil: Antibody Drug Conjugates Market, by Technology

9.1.3.1.4 Brazil: Antibody Drug Conjugates Market, by Application

9.1.3.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.2 Argentina

- 9.1.3.2.1 Overview
- 9.1.3.2.2 Argentina: Antibody Drug Conjugates Market, by Technology
- 9.1.3.2.3 Argentina: Antibody Drug Conjugates Market, by Application
- 9.1.3.2.4 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
- 9.1.3.3 Rest of South & Central America
 - 9.1.3.3.1 Overview
 - 9.1.3.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US\$ Mn)
 - 9.1.3.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
 - 9.1.3.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
 - 9.1.3.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel

10. ANTIBODY DRUG CONJUGATES MARKET-INDUSTRY LANDSCAPE

- 10.1 Overview
- 10.2 Organic Growth Strategies
 - 10.2.1 Overview
- 10.3 Inorganic Growth Strategies
 - 10.3.1 Overview
- 10.4 Companies' Manufacturing Capacities and Capabilities

11. COMPANY PROFILES

- 11.1 Pfizer Inc
 - 11.1.1 Key Facts
 - 11.1.2 Business Description
 - 11.1.3 Products and Services
 - 11.1.4 Financial Overview
 - 11.1.5 SWOT Analysis
 - 11.1.6 Key Developments
- 11.2 Hoffmann-La Roche Ltd
 - 11.2.1 Key Facts
 - 11.2.2 Business Description
 - 11.2.3 Products and Services
 - 11.2.4 Financial Overview
 - 11.2.5 SWOT Analysis

- 11.2.6 Key Developments
- 11.3 GSK Plc
 - 11.3.1 Key Facts
 - 11.3.2 Business Description
 - 11.3.3 Products and Services
 - 11.3.4 Financial Overview
 - 11.3.5 SWOT Analysis
 - 11.3.6 Key Developments
- 11.4 Gilead Sciences Inc
 - 11.4.1 Key Facts
 - 11.4.2 Business Description
 - 11.4.3 Products and Services
 - 11.4.4 Financial Overview
 - 11.4.5 SWOT Analysis
 - 11.4.6 Key Developments
- 11.5 AstraZeneca Plc
 - 11.5.1 Key Facts
 - 11.5.2 Business Description
 - 11.5.3 Products and Services
 - 11.5.4 Financial Overview
 - 11.5.5 SWOT Analysis
 - 11.5.6 Key Developments
- 11.6 Astellas Pharma Inc
 - 11.6.1 Key Facts
 - 11.6.2 Business Description
 - 11.6.3 Products and Services
 - 11.6.4 Financial Overview
 - 11.6.5 SWOT Analysis
 - 11.6.6 Key Developments
- 11.7 Takeda Pharmaceutical Co Ltd
 - 11.7.1 Key Facts
 - 11.7.2 Business Description
 - 11.7.3 Products and Services
 - 11.7.4 Financial Overview
 - 11.7.5 SWOT Analysis
 - 11.7.6 Key Developments

12. APPENDIX

12.1 About Us

12.2 Glossary of Terms

I would like to order

Product name: South & Central America Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Product link: <https://marketpublishers.com/r/S984827E309AEN.html>

Price: US\$ 3,550.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S984827E309AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970